Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSCs for COVID-19 Acute Pulmonary Inflammation
NCT04490486Phase 1Withdrawn
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial of umbilical cord tissue-derived mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms). Primary endpoint: Percent of participants with treatment related Serious Adverse Events at 12 months. Planned start Oct 2022; status: withdrawn.
02
Drugs
umbilical cord tissue-derived mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04490486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490486.